While this immunotherapeutic agent is relatively inconvenient as a personalized vaccine, it seems that selecting the recombinant version of the prostatic acid phosphatase (PAP)—expressed in 95% of prostatic tumor cells—as antigen was critical [2], reaffirming target selection as a key feature in cancer vaccine design. Here, ACP3 is linked to prostate neoplasm.